

BIOCON PHARMA INC.

BALANCE SHEET AS AT MARCH 31, 2019

(All amounts are in United States Dollars, except share data and per share data, unless otherwise stated)

	<u>Note</u>	<u>March 31, 2019</u>	<u>March 31, 2018</u>
ASSETS			
Non-current assets			
Leasehold Improvements	3	1,52,591	1,24,755
Other intangible assets	4	5,79,581	-
Capital work in progress	3	-	52,440
Financial assets			
(i) Other financial assets	5	14,083	14,083
Other non-current assets		-	14,045
Total non-current assets		<u>7,46,255</u>	<u>2,05,323</u>
Current assets			
Inventories	6	66,55,829	16,21,610
Financial assets			
(i) Trade receivables	7	97,15,850	12,82,783
(ii) Cash and cash equivalents	8	35,07,354	46,18,488
Other current assets	9	1,264	1,156
Total current assets		<u>1,98,80,297</u>	<u>75,24,037</u>
TOTAL		<u><u>2,06,26,552</u></u>	<u><u>77,29,360</u></u>
EQUITY AND LIABILITIES			
Equity			
Equity share capital	10(a)	14,00,000	14,00,000
Preference share capital	10(b)	70,00,000	20,00,000
Other equity		4,24,274	1,37,613
Total equity		<u>88,24,274</u>	<u>35,37,613</u>
Current liabilities			
Financial liabilities			
(i) Borrowings	11	-	6,26,425
(ii) Trade payables		1,17,78,890	35,65,322
Other Liabilities		23,388	-
Total current liabilities		<u>1,18,02,278</u>	<u>41,91,747</u>
TOTAL		<u><u>2,06,26,552</u></u>	<u><u>77,29,360</u></u>

BIOCON PHARMA INC.**STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2019****(All amounts are in United States Dollars, except share data and per share data, unless otherwise stated)**

	<u>Note</u>	<u>Year ended March 31, 2019</u>	<u>Year ended March 31, 2018</u>
Income			
Revenue from operations		2,23,20,321	26,19,024
		2,23,20,321	26,19,024
Expenses			
Purchases of traded goods		2,23,55,653	59,49,523
(Increase)/ Decrease in inventories of traded goods	12	(50,34,219)	(13,98,149)
Employee benefits expense	13	11,52,595	8,18,091
Finance Costs		-	26,425
Depreciation and amortisation expense	14	1,02,068	82
Other expenses	15	34,57,563	5,68,425
Total expenses (II)		2,20,33,660	59,64,397
Profit / (Loss) for the year		2,86,661	(33,45,373)
Earnings per share			
Basic and diluted (in Rs.)		2	(24)

The accompanying notes are an integral part of the financial statements.

BIOCON PHARMA INC.

STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2019

(All amounts are in United States Dollars, except share data and per share data, unless otherwise stated)

A. Equity share capital

	March 31, 2019	March 31, 2018
Opening balance	14,00,000	14,00,000
Changes in equity share capital during the year	-	-
Closing balance	14,00,000	14,00,000

B. Preference share capital

	March 31, 2019	March 31, 2018
Opening balance	20,00,000	-
Changes in equity share capital during the year	50,00,000	20,00,000
Closing balance	70,00,000	20,00,000

C. Other equity

Particulars	Retained earnings	Share application money pending allotment	Total other equity
Balance as at April 01, 2017	(15,17,014)	-	(15,17,014)
Application money received / (trf) during the year	-	50,00,000	50,00,000
Profit/(Loss) for the year	(33,45,373)	-	(33,45,373)
Other comprehensive income	-	-	-
Balance as at March 31, 2018	(48,62,387)	50,00,000	1,37,613
Application money received / (trf) during the year	-	-	-
Profit/(Loss) for the year	2,86,661	-	2,86,661
Other comprehensive income	-	-	-
Balance as at December 31, 2018	(45,75,726)	50,00,000	4,24,274

BIOCON PHARMA INC.

Notes to financials statements for the period ended March 31, 2019

(All amounts are in United States Dollars, except share data and per share data, unless otherwise stated)

3. Tangible assets

	Furniture and fixture	Computers	Office equipment	Leasehold improvements	Capital work in progress	Total
Gross carrying amount						
At April 01, 2017	-	-	-	-	-	-
Additions	63,591	53,219	8,027	-	52,440	1,77,276
Disposal	-	-	-	-	-	-
At March 31, 2018	63,591	53,219	8,027	-	52,440	1,77,276
Additions	-	-	39,045	27,440	-	66,485
Disposal	-	-	-	-	(52,440)	(52,440)
At March 31, 2019	63,591	53,219	47,072	27,440	-	1,91,321
Accumulated amortisation						
At April 01, 2017	-	-	-	-	-	-
Depreciation for the year	(29)	(48)	(4)	-	-	(82)
At March 31, 2018	(29)	(48)	(4)	-	-	(82)
Depreciation for the year	(10,599)	(17,700)	(6,912)	(3,439)	-	(38,649)
At March 31, 2019	(10,628)	(17,748)	(6,916)	(3,439)	-	(38,731)
Net carrying amount						
At April 01, 2017	-	-	-	-	-	-
At March 31, 2018	63,562	53,170	8,022	-	52,440	1,77,195
At March 31, 2019	52,963	35,471	40,156	24,001	-	1,52,591

4. Intangible assets

	Marketing rights
Gross carrying amount	
At April 01, 2017	-
Additions	-
Disposal	-
At March 31, 2018	-
Additions	6,43,000
Disposal	-
At March 31, 2019	6,43,000
Accumulated amortisation	
At April 01, 2017	-
Depreciation for the year	-
At March 31, 2018	-
Depreciation for the year	(63,419)
At March 31, 2019	(63,419)
Net carrying amount	
At April 01, 2017	-
At March 31, 2018	-
At March 31, 2019	5,79,581

BIOCON PHARMA INC.

Notes to financials statements for the period ended March 31, 2019

(All amounts are in United States Dollars, except share data and per share data, unless otherwise stated)

	<u>March 31, 2019</u>	<u>March 31, 2018</u>		
5. Other financial assets				
Deposits	14,083	14,083		
	<u>14,083</u>	<u>14,083</u>		
6. Inventories				
Traded goods	66,55,829	16,21,610		
Raw Materials	-	-		
	<u>66,55,829</u>	<u>16,21,610</u>		
7. Trade receivables				
Unsecured, considered good	97,15,850	12,82,783		
	<u>97,15,850</u>	<u>12,82,783</u>		
8. Cash and bank balances				
Cash and cash equivalents				
Balances with banks:				
On current accounts	35,07,354	46,18,488		
Total cash and cash equivalents	<u>35,07,354</u>	<u>46,18,488</u>		
9. Other current assets				
Prepayments	-	1,156		
Advance to suppliers	1,264	-		
	<u>1,264</u>	<u>1,156</u>		
10(a). Share capital				
Authorized share capital				
500,000 shares of stock(March 31, 2017 - 500,000) of USD 10 each	50,00,000	50,00,000		
Issued, subscribed and fully paid-up				
140,000 (March 31, 2017 - 140,000) equity shares of USD 10 each	14,00,000	14,00,000		
200,000 (March 31, 2017 - Nil) preference shares of USD 10 each	70,00,000	20,00,000		
	<u>84,00,000</u>	<u>34,00,000</u>		
Share application money pending allotment				
Application money for preference shares	-	50,00,000		
	<u>-</u>	<u>50,00,000</u>		
(i) Reconciliation of the shares outstanding at the beginning and at the end of the reporting year				
Equity shares	March 31, 2019		March 31, 2018	
	No.	USD	No.	USD
At the beginning of the year	1,40,000	14,00,000	1,40,000	14,00,000
Issued during the year	-	-	-	-
Outstanding at the end of the year	<u>1,40,000</u>	<u>14,00,000</u>	<u>1,40,000</u>	<u>14,00,000</u>
Preference shares	March 31, 2019		March 31, 2018	
	No.	USD	No.	USD
At the beginning of the year	2,00,000	20,00,000	-	-
Issued during the year	5,00,000	50,00,000	2,00,000	20,00,000
Outstanding at the end of the year	<u>7,00,000</u>	<u>70,00,000</u>	<u>2,00,000</u>	<u>20,00,000</u>
(ii) Terms/ rights attached to shares				
Equity shares are at a par value of USD 10 per share. Each holder of equity shares is entitled to one vote per share.				
In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts, if any. The distribution will be in proportion to the number of equity shares held by the shareholders.				
Optionally convertible redeemable cumulative preference shares (OCRPS) are at a par value of USD 10 per share. Each holder of OCRPS is entitled to one vote per share on all matters pertaining to the rights of OCRPS holders.				
(iii) Details of shareholders holding more than 5% shares in the Company				
	March 31, 2019		March 31, 2018	
	No.	% holding	No.	% holding
Equity shares of Rs 10 each fully paid				
Biocon Pharma Limited, the holding company (including shares held through nominees)				
Equity shares of USD 10 each fully paid up	1,40,000	100%	1,40,000	100%
As per records of the Company, including its register of shareholders/ members, the above shareholding represents both legal and beneficial ownerships of shares.				
11. Short term borrowings				
Advances from associate company	-	6,26,425	-	6,26,425
	<u>-</u>	<u>6,26,425</u>	<u>-</u>	<u>6,26,425</u>

BIOCON PHARMA INC.

Notes to financials statements for the period ended March 31, 2019

(All amounts are in United States Dollars, except share data and per share data, unless otherwise stated)

	<u>March 31, 2019</u>	<u>March 31, 2018</u>
<u>12. (Increase)/ Decrease in inventories of traded goods</u>		
Inventory at the beginning of the year		
Traded goods	16,21,610	2,23,461
	<u>16,21,610</u>	<u>2,23,461</u>
Inventory at the end of the year		
Traded goods	66,55,829	16,21,610
	<u>66,55,829</u>	<u>16,21,610</u>
(Increase)/ decrease in inventories	<u>(50,34,219)</u>	<u>(13,98,149)</u>
<u>13. Employee benefits expense</u>		
Salaries, wages and bonus	10,71,387	7,41,574
Share based payment expense	10,651	13,929
Staff welfare expenses	70,557	62,588
	<u>11,52,595</u>	<u>8,18,091</u>
<u>14. Depreciation</u>		
Depreciation of tangible assets	38,649	82
Depreciation of intangible assets	63,419	-
	<u>1,02,068</u>	<u>82</u>
<u>15. Other expenses</u>		
Rent	98,992	70,960
Communication expenses	41	3,183
Travelling and conveyance	17,620	85,536
Professional charges	5,20,063	2,42,755
Insurance	43,626	35,874
Rates, taxes and fees	17,283	6,868
Repairs and Maintenance - PM	2,309	-
Repairs and Maintenance - Bldg	9,123	-
Freight outwards and clearing charges	11,31,201	79,006
Sales promotion expenses	15,70,176	5,711
Printing and stationery	124	2,513
Miscellaneous expenses	47,005	36,019
	<u>34,57,563</u>	<u>5,68,425</u>

BIOCON PHARMA INC.**Notes to the financial statements for the year ended March 31, 2017****(All amounts are in United States Dollars, except share data and per share data, unless otherwise stated)****16. Contingent liabilities and commitments****(i) Capital commitments:**

The estimated amount of contracts remaining to be executed on capital account and not provided for as at March 31, 2017, net of advances, is Rs. Nil (March 31, 2016:- Rs. Nil)

(ii) Contingent liabilities:

The company has no contingent liability as at March 31, 2017 and March 31, 2016.

17. Reconciliation of basic and diluted shares used in computing earnings per share (EPS)

	<u>March 31, 2019</u>	<u>March 31, 2018</u>
<i>Earnings</i>		
Profit / (loss) for the year	2,86,661	(33,45,373)
<i>Shares</i>		
Basic outstanding shares	1,40,000	1,40,000
Add: Weighted average shares issued during the year	-	-
Weighted average shares used for computing basic and diluted EPS	<u>1,40,000</u>	<u>1,40,000</u>
Earnings / (Loss) per share		
Basic and Diluted (in Rs.)	2	(24)